Free tool
FAERS Monitor: Pyzchiva
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761425 or its brand name (Pyzchiva, Ustekinumab-Ttwe). Reports on generic versions are filed under their own applications.
Reports
191
Serious
189
99% of reports
Hospitalization
59
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- crohn^s disease27
- drug ineffective20
- product substitution issue18
- dizziness15
- abdominal pain14
- infection14
- condition aggravated13
- diarrhoea12
- off label use11
- syncope11
- arthralgia9
- device difficult to use9
- fatigue9
- gastritis9
- headache8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 6 |
| 2025 | 112 |
| 2026 | 73 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,968 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gastritisSignal | 9 | 37.7 | 19.9 | 286 |
| product substitution issueSignal | 18 | 34.4 | 22.2 | 553 |
| device difficult to useSignal | 9 | 15.0 | 7.9 | 104 |
| syncopeSignal | 11 | 12.1 | 6.8 | 102 |
| infectionSignal | 14 | 10.7 | 6.4 | 114 |
| abdominal painSignal | 14 | 6.6 | 4.0 | 62 |
| condition aggravatedSignal | 13 | 4.7 | 2.8 | 35 |
| dizzinessSignal | 15 | 3.3 | 2.0 | 22 |
| arthralgiaSignal | 9 | 2.4 | 1.3 | 6 |
| diarrhoeaSignal | 12 | 2.0 | 1.2 | 6 |
| drug ineffective | 20 | 1.7 | 1.1 | 5 |
| headache | 8 | 1.4 | 0.7 | 1 |
| off label use | 11 | 1.4 | 0.8 | 1 |
| fatigue | 9 | 1.3 | 0.7 | 0 |
| crohn^s disease | 27 | 0.0 | 0.0 | 2,867,009 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.